Operator
Good morning, and welcome to the United Therapeutics Corporation First Quarter 2021 Earnings Call. My name is Phyllis, and I will be your conference operator today. [Operator Instructions]
I will now turn the conference call over to Mr. Dewey Steadman, Head of Investor Relations at the United Therapeutics.
Dewey Steadman
Head of Investor Relations
Good morning. It s my pleasure to welcome you to the United Therapeutics Corporation First Quarter 2021 Earnings Call. Accompanying me on today s call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Mr. Michael Benkowitz, our President and Chief Operating Officer; Mr. James Edgemond, our Chief Financial Officer and Treasurer; and Dr. Leigh Peterson, our Senior Vice President of Product Development. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to dif
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator
Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. My name is Kenzie, and I will be your conference operator today. [Operator Instructions]
I will now turn the conference call over to Mr. Dewey Steadman, Head of Investor Relations at United Therapeutics.
Dewey Steadman
Head of Investor Relations
Good morning. It s my pleasure to welcome you to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. Accompanying me on today s call are Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. Michael Benkowitz, our President and Chief Operating Officer; Mr. James Edgemond, our Chief Financial Officer and Treasurer; and Dr. Leigh Peterson, Vice President of Product Development. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially.